Halozyme Therapeutics, Inc. (HALO) Set to Announce Quarterly Earnings on Tuesday
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is scheduled to issue its quarterly earnings data after the market closes on Tuesday, November 7th. Analysts expect the company to announce earnings of $0.06 per share for the quarter.
Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02. The business had revenue of $33.80 million for the quarter, compared to analysts’ expectations of $31.76 million. The company’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same period last year, the business posted ($0.21) EPS. On average, analysts expect Halozyme Therapeutics to post $-0.02 EPS for the current fiscal year and $-0.83 EPS for the next fiscal year.
Halozyme Therapeutics, Inc. (NASDAQ HALO) traded up 0.91% on Tuesday, reaching $17.75. 201,005 shares of the company’s stock were exchanged. The stock’s market cap is $2.38 billion. Halozyme Therapeutics, Inc. has a one year low of $8.18 and a one year high of $18.43. The firm has a 50 day moving average of $16.83 and a 200-day moving average of $14.10.
HALO has been the topic of a number of recent analyst reports. Canaccord Genuity set a $16.00 target price on shares of Halozyme Therapeutics and gave the company a “buy” rating in a research report on Wednesday, July 26th. Jefferies Group LLC reiterated an “underperform” rating and set a $7.00 price target (up from $6.75) on shares of Halozyme Therapeutics in a research note on Thursday, August 10th. Piper Jaffray Companies set a $20.00 price target on shares of Halozyme Therapeutics and gave the stock a “buy” rating in a research note on Thursday, August 10th. Zacks Investment Research upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research note on Friday, August 11th. Finally, BidaskClub lowered shares of Halozyme Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 18th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $17.00.
ILLEGAL ACTIVITY WARNING: “Halozyme Therapeutics, Inc. (HALO) Set to Announce Quarterly Earnings on Tuesday” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/31/halozyme-therapeutics-inc-halo-set-to-announce-quarterly-earnings-on-tuesday.html.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.